Joyce Slingerland M.D., Ph.D.
Associate Director, Translational Research; Director, Braman Family Breast Cancer Institute
A native of Canada, Dr. Slingerland received her M.D. from the University of Toronto in 1983, followed by a Fellowship in Internal Medicine with the Royal College of Physicians and Surgeons in Canada. In 1987, she was certified by the American Board in Internal Medicine and in Medical Oncology by the Royal College of Physicians and Surgeons.
In August of 2002, Dr. Slingerland came to the University of Miami School of Medicine as the Director of the Braman Breast Cancer Institute, Sylvester Comprehensive Cancer Center, where she is working to expand and coordinate research efforts on breast cancer from many disciplines. Dr. Slingerland is also Professor of Medicine with a graduate appointment in the Department of Biochemistry and Molecular Biology at the University of Miami, as well as a member of the senior leadership of the UMSCCC and Co-Program Leader of the UMSCCC’s Molecular Oncology and Experimental Therapeutics Program. She also serves as Interim Associate Director, Translational Research.
Dr. Slingerland continues her medical practice devoted entirely to breast cancer patients at the Sylvester Comprehensive Cancer Center and the Jackson Memorial Hospital. She has published over 50 articles and reviews in addition to several book chapters and has received numerous awards. The Slingerland’s lab has been funded by the Canadian NCI’s Breast Cancer Research Initiative and by the DOD Breast Cancer Research Program and now the US NCI. Her research has provided insights on how cancers escape negative growth controls. Dr. Slingerland has made the innovative discovery of the cell cycle inhibitor, p27, and showed that p27 deregulation is prognostic of poor patient outcome and leads to antiestrogen resistance in estrogen receptor positive breast cancers.